ST生物(000504.SZ):聘任遊昌喬為公司總經理
格隆匯 6 月 17日丨ST生物(000504.SZ)公佈,公司第十屆董事會第十四次臨時會議以通訊表決方式召開,會議審議通過了《關於聘任總經理的議案》。公司董事會同意聘任遊昌喬為公司總經理,任期自本次董事會審議通過之日起至本屆董事會屆滿之日止。
遊昌喬,男,1973年出生,東北大學本科、中國社會科學院在職研究生、清華大學EMBA畢業,曾在MIT、Stanford先後進行全球創新及領導力課程培訓,有近20年生物及醫療科技職業經歷,系華中科技大學兼職教授、浙江大學兼職專業碩士導師。1995年7月-1998年6月三株集團任企劃、區域經理;1999年1月-2007年10月福建科康生物技術有限公司任營銷總經理;2008年2月-2011年2月廣東丸美生物技術股份有限公司任副總裁;2013年12月-2020年6月微醫貝聯(上海)信息科技有限公司創始人、董事長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.